September 3, 2014 -- BeiGene, a Beijing innovative drug development company, signed a contract manufacturing agreement with Boehringer Ingelheim that calls for BI to produce BeiGene's drugs at its Shanghai biopharma facility. BI's $82 million plant, located in the Zhangjiang Hi-Tech Park, is currently under construction and should be complete next year. Last week, in a separate announcement, BeiGene said its third molecule had started a clinical trial, underscoring its need for a CMO partner.
Help employers find you! Check out all the jobs and post your resume.
